By linking tissue inflammation with decreased cell sensitivity to the effects of type I IFN, these findings help to explain the decreased sensitivity of melanoma to the antitumorigenic effects of endogenous as well as therapeutically administered exogenous IFN-α/β [69]. This evidence concerns the gene IFNA1 and melanoma.